Allele Biotechnology & Pharmaceuticals, Inc. (Allele), a San Diego-based technology development and cell manufacturing ...

The BLA was resubmitted in 2025, after Atara and the FDA aligned on the criteria and addressed the initial CRL conditions.

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.

In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...

A team of researchers led by bioengineer Shaochen Chen will use 3D printing techniques to shape stem cells produced by local firm Allele Biotechnology ...

The U.S. Food and Drug Administration declined to approve Atara Biotherapeutics' cell therapy for a ​rare form of blood ...

Billiontoone (NASDAQ:BLLN) used its presentation at the JPMorgan Healthcare Conference to highlight what management described as a “single molecule” next-generation sequencing platform that it ...

The FDA has issued a second complete response letter to Atara Biotherapeutics for its biologicals license application of ...

Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

Learn more about whether Perrigo Company plc or Wave Life Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A second complete response letter issued by the U.S. FDA for Atara Biotherapeutics Inc.’s allogeneic T-cell immunotherapy Ebvallo (tabelecleucel) for Epstein-Barr virus positive post-transplant ...

Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...